Search Result

Results for "

β-cell

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amylases (1) Amylin Receptor (3) Antibiotic (1) Antifolate (1) Apoptosis (10) Autophagy (1) Bacterial (1) Calcium Channel (2) CD3 (1) CGRP Receptor (1) Dipeptidyl Peptidase (3) DNA Alkylator/Crosslinker (1) DNA/RNA Synthesis (1) DYRK (4) Endogenous Metabolite (2) Free Fatty Acid Receptor (2) GCGR (6) GLP Receptor (1) Glucokinase (3) Glucosidase (1) GPR119 (3) GSK-3 (3) Insulin Receptor (2) Lipoxygenase (1) mAChR (1) Phospholipase (2) Potassium Channel (17) Prostaglandin Receptor (1) PTHR (1) Ras (1) TRP Channel (1)
By Research Areas:	Cancer (3) Cardiovascular Disease (10) Endocrinology (3) Infection (1) Inflammation/Immunology (6) Metabolic Disease (58) Neurological Disease (4)

By Targets:

Amylases (1)

Amylin Receptor (3)

Antibiotic (1)

Antifolate (1)

Apoptosis (10)

Autophagy (1)

Bacterial (1)

Calcium Channel (2)

CD3 (1)

CGRP Receptor (1)

Dipeptidyl Peptidase (3)

DNA Alkylator/Crosslinker (1)

DNA/RNA Synthesis (1)

DYRK (4)

Endogenous Metabolite (2)

Free Fatty Acid Receptor (2)

GCGR (6)

GLP Receptor (1)

Glucokinase (3)

Glucosidase (1)

GPR119 (3)

GSK-3 (3)

Insulin Receptor (2)

Lipoxygenase (1)

mAChR (1)

Phospholipase (2)

Potassium Channel (17)

Prostaglandin Receptor (1)

PTHR (1)

Ras (1)

TRP Channel (1)

By Research Areas:

Cancer (3)

Cardiovascular Disease (10)

Endocrinology (3)

Infection (1)

Inflammation/Immunology (6)

Metabolic Disease (58)

Neurological Disease (4)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Itk TOPK NAMPT ALCAM/CD166 GDNF Receptor BCL6 Tim3

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-109030

Dorzagliatin HMS5552	Glucokinase	Metabolic Disease
Dorzagliatin (HMS5552), a dual-acting glucokinase (GK) activator, improves glycaemic control and pancreatic β-cell function in type 2 diabetes .

HY-B1021

Vincamine	Free Fatty Acid Receptor	Cardiovascular Disease Metabolic Disease
Vincamine is a monoterpenoid indole alkaloid extracted from the Madagascar periwinkle. Vincamine is a peripheral vasodilator and exerts a selective vasoregulator action on the brain microcapilar circulation . Vincamine is a GPR40 agonist and acts as a β-cell protector by ameliorating β-cell dysfunction and promoting glucose-stimulated insulin secretion (GSIS). Vincamine improves glucose homeostasis in vivo, and has the potential for the type 2 diabetes mellitus (T2DM) research .

HY-N3419

Kobusone	Others	Metabolic Disease
Kobusone is a natural compound isolated form Aquilaria sinensis. kobusone can stimulate islet β-cell replication in vivo, and has the potential to be used in diabetic study .

HY-120711

BRD0476 ML187	Apoptosis	Metabolic Disease
BRD0476 is an inhibitor of pancreatic β-cell apoptosis with an EC₅₀ value of 0.78 μM and a maximal inhibitory activity of 99%. BRD0476 can be used in diabetes-related research .

HY-129736A

P32/98	Dipeptidyl Peptidase	Metabolic Disease
P32/98 a potent inhibitor of dipeptidyl peptidase IV with a K_i value of 130 nM. P32/98 improves glucose tolerance, insulin sensitivity and β-cell responsiveness in fatty Zucker rat model .

HY-129736

P32/98 hemifumarate	Dipeptidyl Peptidase	Metabolic Disease
P32/98 hemifumarateis a potent inhibitor of dipeptidyl peptidase IV with a K_i value of 130 nM. P32/98 hemifumarate improves glucose tolerance, insulin sensitivity and β-cell responsiveness in fatty Zucker rat model .

HY-138990

GK563	Phospholipase Apoptosis	Inflammation/Immunology
GK563 is a selective Ca ²⁺-independent phospholipase A₂ (GVIA iPLA₂) inhibitor with an IC₅₀ value of 1 nM. GK563 is 22000 times more active against GVIA iPLA₂ than GIVA cPLA₂. GK563 reduces β-cell apoptosis induced by proinflammatory cytokines, raising the possibility that it can be beneficial in countering autoimmune diseases, such as type 1 diabetes .

HY-142295

GNF2133	DYRK	Metabolic Disease
GNF2133 is a potent, selective and orally active DYRK1A inhibitor with IC₅₀s of 0.0062, >50 µM for DYRK1A and GSK3β, respectively. GNF2133 shows good proliferation potency and efficacy on rat and human primary β-cell. GNF2133 significantly improves glucose disposal capacity and increases insulin secretion. GNF2133 has the potential for the research of type 1 diabetes .

HY-142295A

GNF2133 hydrochloride	DYRK	Metabolic Disease
GNF2133 hydrochloride is a potent, selective and orally active DYRK1A inhibitor with IC₅₀s of 0.0062, >50 µM for DYRK1A and GSK3β, respectively. GNF2133 hydrochloride shows good proliferation potency and efficacy on rat and human primary β-cell. GNF2133 hydrochloride significantly improves glucose disposal capacity and increases insulin secretion. GNF2133 hydrochloride has the potential for the research of type 1 diabetes .

HY-111310

ML351	Lipoxygenase	Neurological Disease Metabolic Disease
ML351 is a potent and highly specific 15-LOX-1 inhibitor with an IC₅₀ of 200 nM. ML351 shows excellent selectivity (>250-fold) versus the related isozymes, 5-LOX, platelet 12-LOX, 15-LOX-2, ovine COX-1, and human COX-2 . ML351 prevents dysglycemia and reduces β-cell oxidative stress in nonobese diabetic mouse model of T1D .

HY-15564

AR 231453 1 Publications Verification	GPR119	Metabolic Disease
AR 231453 is a potent, specific and orally available GPR119 agonist. AR 231453 can stimulate β-cell replication and improve islet graft function s .

HY-147503

Vin-F03	Apoptosis	Cardiovascular Disease
Vin-F03 is a potent pancreatic β-cells protective agent with an EC₅₀ of 0.27 µM. Vin-F03 effectively promotes β-cell survival and protects β-cells from STZ-induced apoptosis. Vin-F03 can be used for type 2 diabetes mellitus research .

HY-147502

Vin-C01	Apoptosis	Cardiovascular Disease
Vin-C01 is a potent pancreatic β-cells protective agent with an EC₅₀ of 0.22 µM. Vin-C01 effectively promotes β-cell survival and protects β-cells from STZ-induced apoptosis. Vin-C01 can be used for type 2 diabetes mellitus research .

HY-147760

Dyrk1A-IN-2	DYRK	Metabolic Disease
Dyrk1A-IN-2 (Compound 63) is a DYRK1A inhibitor with an EC₅₀ of 37 nM. Dyrk1A-IN-2 exhibits highly potent human β-cell replication-promoting activity and low cytotoxicity .

HY-B0422

Nateglinide A4166; Senaglinide	Potassium Channel Dipeptidyl Peptidase	Metabolic Disease
Nateglinide, a D-phenylalanine derivative, is an orally active and short-acting insulinotropic agent and a DPP IV inhibitor. Nateglinide inhibits ATP-sensitive K ⁺ channels in pancreatic β-cells. Nateglinide is used for the treatment of type 2 (non-insulin-dependent) diabetes mellitus .

HY-129492

GNF4877 1 Publications Verification	DYRK GSK-3	Metabolic Disease
GNF4877 is a potent DYRK1A and GSK3β inhibitor with IC₅₀s of 6 nM and 16 nM, respectively, which leads to blockade of nuclear factor of activated T-cells (NFATc) nuclear export and increased β-cell proliferation (EC₅₀ of 0.66 μM for mouse β (R7T1) cells) .

HY-P10018

Bamadutide SAR425899	GLP Receptor GCGR	Metabolic Disease
Bamadutide (SAR425899) is a potent dual glucagon-like peptide-1 receptor/glucagon receptor agonist. Bamadutide (SAR425899) improves postprandial glucose control by significantly enhancing β-cell function and slowing glucose absorption rate in vivo. Bamadutide (SAR425899)can be used for type 2 diabetes research .

HY-B2028

Propargite
Propargite is a pesticide used to kill mites. Propargite induces β-cell necrosis preceded by DNA damage. Propargite induces MIN6 cell death with an IC₅₀?of?1?μM . Propargite is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-16673

PSN632408	GPR119	Metabolic Disease
PSN632408, a selective, orally active GPR119 agonist, shows similar potency to OEA at both recombinant mouse and human GPR119 receptors (EC₅₀=5.6 and 7.9 uM, respectively). PSN632408 can stimulate β-cell replication and improve islet graft function. PSN632408 has the potential for the research of obesity and related metabolic disorders .

HY-124424

VU0071063	Potassium Channel	Others Neurological Disease
VU0071063 is a potent and specific Kir6.2/SUR1 opener (EC₅₀=7.44 μM) and can be used for investigating Kir6.2/SUR1 expressed in the pancreas and brain. VU0071063 inhibits insulin secretion by inducing hyperpolarization of β-cell membrane potential. VU0071063 chemotype has a very steep structure-activity relationships .

HY-19618

BRD3308
BRD3308 is a highly selective HDAC3 inhibitor with an IC₅₀ of 54 nM. BRD3308 is 23-fold selectivity for HDAC3 over HDAC1 (IC₅₀ of 1.26 μM) or HDAC2 (IC₅₀ of 1.34 μM). BRD3308 suppresses pancreatic β-cell apoptosis induced by inflammatory cytokines or glucolipotoxic stress, and increases functional insulin release. BRD3308 activates HIV-1 transcription and disrupts HIV-1 latency .

HY-P3622

(Ser8)-GLP-1 (7-36) amide, human	GCGR	Metabolic Disease
(Ser8)-GLP-1 (7-36) amide, human is a glucagon-like peptide 1 amide derived from glucagonogen, a cleavage product of the GLP-1 (1-36) amide peptide. (Ser8)-GLP-1 (7-36) amide, human is an entero-insulinotropic hormone that causes glucose-dependent release of insulin from pancreatic β-cells and affects gastrointestinal motility and secretion .

HY-P0054

GLP-1(7-36), amide acetate 5+ Cited Publications Glucagon-like peptide-1 (GLP-1)(7-36), amide acetate; Human GLP-1 (7-36), amide acetate	GCGR	Metabolic Disease
GLP-1(7-36), amide acetate is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells.

HY-B0753

Gliclazide 2 Publications Verification S1702; SE1702	Potassium Channel	Cardiovascular Disease
Gliclazide (S1702) is a whole-cell beta-cell ATP-sensitive potassium currents blocker with an IC₅₀ of 184 nM. Gliclazide is used as an antidiabetic .

HY-P0054B

GLP-1(7-36), amide TFA 5+ Cited Publications Glucagon-like peptide-1 (GLP-1)(7-36), amide TFA; Human GLP-1 (7-36), amide TFA	GCGR	Metabolic Disease
GLP-1(7-36), amide TFA is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells .

HY-P1156

Insulin(cattle) 5+ Cited Publications	Insulin Receptor	Metabolic Disease Endocrinology
Insulin cattle is a two-chain polypeptide hormone produced in vivo in the pancreatic β cells. Insulin cattle has often been used as growth supplement in culturing cells.

HY-P1156A

Insulin(cattle/bovine), purity>95% 5+ Cited Publications	Insulin Receptor	Metabolic Disease Endocrinology
Insulin cattle is a two-chain polypeptide hormone produced in vivo in the pancreatic β cells. Insulin cattle has often been used as growth supplement in culturing cells.

HY-135337

Ethyl tosylcarbamate	Potassium Channel	Metabolic Disease
Ethyl tosylcarbamate is an intermediate in the synthesis of Gliclazide (G409877) . Gliclazide is a whole-cell beta-cell ATP-sensitive potassium currents blocker with an IC₅₀ of 184 nM .

HY-124735

RH01687	Others	Metabolic Disease
RH01687 is a compound that can protect pancreatic β cells against endoplasmic reticulum stress-induced cell death. RH01687 has the potential for the research of diabetes .

HY-N9363

Corymbiferin	Others	Metabolic Disease
Corymbiferin is one of active constituents, responsible for anti-diabetic properties. Corymbiferin improves antioxidant capacity and carbohydrate metabolism in diabetic rats, along with the improvement of histopathology of livers and pancreatic β cells .

HY-12074

Cazpaullone	GSK-3	Metabolic Disease
Cazpaullone is a glycogen synthase kinase-3 (GSK-3) inhibitor. Cazpaullone can activate pancreatic beta cell protection and replication. Cazpaullone can be used for the research of diabetes .

HY-119322

Tifenazoxide NN414	Potassium Channel	Metabolic Disease
Tifenazoxide (NN414) is a potent, orally active and SUR1/Kir6.2 selective K ^ATP channels opener. Tifenazoxide has antidiabetic effect, can inhibit glucose stimulated insulin release in vitro and in vivo, and has a beneficial effect on glucose homeostasis .

HY-P3101

GLP-1(28-36)amide	GCGR	Cardiovascular Disease Metabolic Disease
GLP-1(28-36)amide, a C-terminal nonapeptide of GLP-1, is a major product derived from the cleavage of GLP-1 by the neutral endopeptidase (NEP). GLP-1(28-36)amide is an antioxidant and targets to mitochondrion, inhibits mitochondrial permeability transition (MPT). GLP-1(28-36)amide has anti-diabetic and cardioprotection effects .

HY-P3101A

GLP-1(28-36)amide TFA	GCGR	Cardiovascular Disease Metabolic Disease
GLP-1(28-36)amide TFA, a C-terminal nonapeptide of GLP-1, is a major product derived from the cleavage of GLP-1 by the neutral endopeptidase (NEP). GLP-1(28-36)amide TFA is an antioxidant and targets to mitochondrion, inhibits mitochondrial permeability transition (MPT). GLP-1(28-36)amide TFA has anti-diabetic and cardioprotection effects .

HY-P1980

A-71915 TFA	Apoptosis	Metabolic Disease
A-71915 (TFA) is a selective inhibitor of ANP receptor (atrial natriuretic peptide-receptor), induces apoptosis and decreases insulin secretion in RINm5F pancreatic β-cells .

HY-12461

WS6

Others Inflammation/Immunology

WS6 is a novel small molecule that promotes β cell proliferation in rodent and human primary islets with EC50 of 0.28 uM(R7T1 cell viability).

WS6	Others	Inflammation/Immunology
WS6 is a novel small molecule that promotes β cell proliferation in rodent and human primary islets with EC50 of 0.28 uM(R7T1 cell viability).

HY-12462

WS3	Others	Inflammation/Immunology
WS3 is a novel proliferative molecule that promotes pancreatic β cell proliferation in rodent and human primary islets. WS3 can be used for the research of type 1 diabetes .

HY-P5796

FS-2	Calcium Channel	Neurological Disease
FS-2 is a potent and specific L-type Ca_V channel inhibitor. FS-2 inhibits high K ⁺ or glucose induced L-type Ca ²⁺ influx in RIN beta cells .

HY-B0401A

Tolbutamide sodium	Apoptosis	Metabolic Disease
Tolbutamide sodium is a potent and orally active antidiabetic agent. Tolbutamide sodium induces apoptosis in a Ca ²⁺ dependent manner in pancreatic β-cells. Tolbutamide sodium has the potential for the research of non-insulin-dependent diabetes mellitus .

HY-B0753R

Gliclazide (Standard) S1702 (Standard); SE1702 (Standard)	Potassium Channel	Cardiovascular Disease
Gliclazide (Standard) is the analytical standard of Gliclazide. This product is intended for research and analytical applications. Gliclazide (S1702) is a whole-cell beta-cell ATP-sensitive potassium currents blocker with an IC₅₀ of 184 nM. Gliclazide is used as an antidiabetic .

HY-N7729

Sekikaic acid	Amylases Glucosidase	Metabolic Disease
Sekikaic acid is an α-glucosidase (Glucosidase) and α-amylase (Amylases) inhibitor with hypolipidemic, antioxidant and antidiabetic activities. Sekikaic acid significantly reduces LDL, total cholesterol, and total glyceride levels and causes pancreatic beta cell regeneration .

HY-N10587

Catechin 7-O-β-D-glucopyranoside	Others	Inflammation/Immunology
Catechin 7-O-beta-D-glucopyranoside is an orally active natural product found in Ulmus davidiana and Paeonia obovata. Catechin 7-O-β-D-glucopyranoside shows antioxidant and anti-inflammatory activities, and attenuates mitochondrial dysfunction. Catechin 7-O-beta-D-glucopyranoside can be used in intestinal inflammatory disease research .

HY-B0753S

Gliclazide-d4	Potassium Channel	Cardiovascular Disease
Gliclazide-d₄ (S1702 D4) is the deuterium labeled Gliclazide. Gliclazide (S1702) is a whole-cell beta-cell ATP-sensitive potassium currents blocker with an IC50 of 184 nM. Gliclazide is used as an antidiabetic[1].

HY-P99222

Teplizumab MGA-031; PRV-031	CD3	Metabolic Disease
Teplizumab (MGA-031) is a Fc receptor non-binding anti-human CD3 monoclonal antibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes .

HY-P1871

Amylin (IAPP), feline	Amylin Receptor	Metabolic Disease
Amylin (IAPP), feline is a 37-amino acid polypeptide from feline. Amylin (IAPP), feline is one of the major secretory products of β-cells of the pancreatic islets. Amylin (IAPP), feline is a regulatory peptide, which inhibits insulin and glucagon secretion .

HY-108589

PNU 37883 hydrochloride PNU 37883A	Potassium Channel	Neurological Disease
PNU 37883 hydrochloride (PNU 37883A) is a selective vascular ATP-sensitive potassium (Kir6, K_ATP) channels blocker. PNU 37883 hydrochloride has diuretic effects with specific binding in kidney and vascular smooth muscle rather than in brain or pancreatic beta cells .

HY-P1871A

Amylin (IAPP), feline TFA	Amylin Receptor	Metabolic Disease
Amylin (IAPP), feline TFA is a 37-amino acid polypeptide from feline. Amylin (IAPP), feline TFA is one of the major secretory products of β-cells of the pancreatic islets. Amylin (IAPP), feline TFA is a regulatory peptide, which inhibits insulin and glucagon secretion .

HY-106288

Human PTHrP-(1-36)	PTHR	Cancer
Human PTHrP-(1-36) is a secretory form of PTHrP with anticalciuric effects. Human PTHrP-(1-36) enhances beta cell function and proliferation. Human PTHrP-(1-36) can be used in the research of humoral hypercalcemia of malignancy (HHM) and hyperparathyroidism .

HY-13753

Streptozotocin Maximum Cited Publications 39 Publications Verification Streptozocin; NSC-85998; U 9889	DNA/RNA Synthesis DNA Alkylator/Crosslinker Autophagy Bacterial Antibiotic Apoptosis	Infection Cancer
Streptozotocin (Streptozocin) is an antibiotic widely used in experimental animal models of induced diabetes. Streptozotocin enters B cells via the glucose transporter (GLUT2) and causes the alkylation of DNA ( DNA-methylating ). Streptozotocin can induce the apoptosis of β cells .

HY-107651

VU 0365114 1 Publications Verification	mAChR	Metabolic Disease
VU 0365114 is a selective mAChR M₅ positive allosteric modulator, with an EC₅₀ of 2.7 μM, and >30 μM for M1, M2, M3 and M4 receptors. VU 0365114 increases insulin secretion stimulated by ACh in human β-cells .

Cat. No.	Product Name	Target	Research Area

HY-105063

DiaPep277	Peptides	Metabolic Disease Inflammation/Immunology
DiaPep277 is a 24 amino acid peptide derived from positions 437-460 in HSP60. DiaPep277 arrests the progression of β-cell destruction in NOD mice. DiaPep277 has an immune modulatory effect on diabetogenic T cells in animal models of diabetes .

HY-P10018

Bamadutide SAR425899	GLP Receptor GCGR	Metabolic Disease
Bamadutide (SAR425899) is a potent dual glucagon-like peptide-1 receptor/glucagon receptor agonist. Bamadutide (SAR425899) improves postprandial glucose control by significantly enhancing β-cell function and slowing glucose absorption rate in vivo. Bamadutide (SAR425899)can be used for type 2 diabetes research .

HY-P3622

(Ser8)-GLP-1 (7-36) amide, human	GCGR	Metabolic Disease
(Ser8)-GLP-1 (7-36) amide, human is a glucagon-like peptide 1 amide derived from glucagonogen, a cleavage product of the GLP-1 (1-36) amide peptide. (Ser8)-GLP-1 (7-36) amide, human is an entero-insulinotropic hormone that causes glucose-dependent release of insulin from pancreatic β-cells and affects gastrointestinal motility and secretion .

HY-P1475

C-Peptide, dog

C-Peptide (dog)
Peptides Metabolic Disease

C-Peptide, dog is a component of proinsulin, released from pancreatic beta cells into blood together with insulin.

HY-P5390

GIP, rat	Peptides	Others
GIP, rat is a biological active peptide. (GIP (Glucose-dependent Insulinotropic Polypeptide or also known as Gastric Inhibitory Polypeptide) is a 42-amino acid peptide released by the K cells of the duodenum and jejunum in response to food intake. GIP, together with GLP (Gastric-like Peptide) are members of the hormone peptide family of Incretins which stimulate insulin secretion from pancreatic islet β-cells, and also appears to promote beta cell proliferation and beta cell survival. Recent studies suggest that GIP plays a role in lipid homeostasis and possibly in the pathogenesis of obesity.)

HY-P5390A

GIP, rat TFA	Peptides	Others
GIP, rat TFA is a bioactive peptide of rat origin. (GIP (glucose-dependent insulinotropic polypeptide or also known as gastric inhibitory polypeptide) is a 42-amino acid peptide released by K cells in the duodenum and jejunum in response to food intake. GIP and GLP (gastric-like peptide) are both intestinal A member of the insulinotropic hormone peptide family that stimulates insulin secretion from pancreatic beta cells and appears to also promote beta cell proliferation and beta cell survival. Recent studies suggest that GIP plays a role in lipid homeostasis and may play a role in the pathogenesis of obesity function in the mechanism.

HY-P0054

GLP-1(7-36), amide acetate Maximum Cited Publications 7 Publications Verification Glucagon-like peptide-1 (GLP-1)(7-36), amide acetate; Human GLP-1 (7-36), amide acetate	GCGR	Metabolic Disease
GLP-1(7-36), amide acetate is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells.

HY-P4813

Preptin (rat)

Peptides Metabolic Disease

Preptin, an osteogenic peptide product of the pancreatic beta-cell, corresponds to Asp ⁶⁹-Leu ¹⁰² of pro-IGF-II .

HY-P0054B

GLP-1(7-36), amide TFA Maximum Cited Publications 7 Publications Verification Glucagon-like peptide-1 (GLP-1)(7-36), amide TFA; Human GLP-1 (7-36), amide TFA	GCGR	Metabolic Disease
GLP-1(7-36), amide TFA is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells .

HY-P1156

Insulin(cattle) 5+ Cited Publications	Insulin Receptor	Metabolic Disease Endocrinology
Insulin cattle is a two-chain polypeptide hormone produced in vivo in the pancreatic β cells. Insulin cattle has often been used as growth supplement in culturing cells.

HY-P1156A

Insulin(cattle/bovine), purity>95% 5+ Cited Publications	Insulin Receptor	Metabolic Disease Endocrinology
Insulin cattle is a two-chain polypeptide hormone produced in vivo in the pancreatic β cells. Insulin cattle has often been used as growth supplement in culturing cells.

HY-P3864

Pancreastatin (37-52), human	Peptides	Metabolic Disease
Pancreastatin (37-52), human is a pancreastatin fragment. Pancreastatin a CgA-derived peptide (CgA residues 250–301) with biological activity, inhibited the releasing of insulin by islet beta cells .

HY-P3101

GLP-1(28-36)amide	GCGR	Cardiovascular Disease Metabolic Disease
GLP-1(28-36)amide, a C-terminal nonapeptide of GLP-1, is a major product derived from the cleavage of GLP-1 by the neutral endopeptidase (NEP). GLP-1(28-36)amide is an antioxidant and targets to mitochondrion, inhibits mitochondrial permeability transition (MPT). GLP-1(28-36)amide has anti-diabetic and cardioprotection effects .

HY-P3101A

GLP-1(28-36)amide TFA	GCGR	Cardiovascular Disease Metabolic Disease
GLP-1(28-36)amide TFA, a C-terminal nonapeptide of GLP-1, is a major product derived from the cleavage of GLP-1 by the neutral endopeptidase (NEP). GLP-1(28-36)amide TFA is an antioxidant and targets to mitochondrion, inhibits mitochondrial permeability transition (MPT). GLP-1(28-36)amide TFA has anti-diabetic and cardioprotection effects .

HY-P1980

A-71915 TFA	Apoptosis	Metabolic Disease
A-71915 (TFA) is a selective inhibitor of ANP receptor (atrial natriuretic peptide-receptor), induces apoptosis and decreases insulin secretion in RINm5F pancreatic β-cells .

HY-P5796

FS-2

Calcium Channel Neurological Disease

FS-2 is a potent and specific L-type Ca_V channel inhibitor. FS-2 inhibits high K ⁺ or glucose induced L-type Ca ²⁺ influx in RIN beta cells .

HY-P1871

Amylin (IAPP), feline	Amylin Receptor	Metabolic Disease
Amylin (IAPP), feline is a 37-amino acid polypeptide from feline. Amylin (IAPP), feline is one of the major secretory products of β-cells of the pancreatic islets. Amylin (IAPP), feline is a regulatory peptide, which inhibits insulin and glucagon secretion .

HY-P1871A

Amylin (IAPP), feline TFA	Amylin Receptor	Metabolic Disease
Amylin (IAPP), feline TFA is a 37-amino acid polypeptide from feline. Amylin (IAPP), feline TFA is one of the major secretory products of β-cells of the pancreatic islets. Amylin (IAPP), feline TFA is a regulatory peptide, which inhibits insulin and glucagon secretion .

HY-106288

Human PTHrP-(1-36)	PTHR	Cancer
Human PTHrP-(1-36) is a secretory form of PTHrP with anticalciuric effects. Human PTHrP-(1-36) enhances beta cell function and proliferation. Human PTHrP-(1-36) can be used in the research of humoral hypercalcemia of malignancy (HHM) and hyperparathyroidism .

HY-P2989

Pyruvate carboxylase	Endogenous Metabolite	Metabolic Disease
Pyruvate carboxylase is a biotin-containing enzyme that catalyzes the HCO3 ⁻ and MgATP dependent carboxylation of pyruvate to form oxaloacetate. Pyruvate carboxylase plays an essential role in controlling whole-body energetics through regulation of gluconeogenesis in the liver, synthesis of fatty acids in adipocytes, and insulin secretion in pancreatic β cells .

HY-P1072

PHM-27 (human)	CGRP Receptor	Cardiovascular Disease Metabolic Disease
PHM-27 (human) is a human prepro-vasoactive intestinal polypeptide (27 amino acid). PHM-27 (human) is a potent the human calcitonin receptor agonist with an EC₅₀ of 11 nM. PHM-27 (human) efficiently enhances glucose-induced insulin secretion from beta cells by an autocrine mechanism .

HY-P2501

Amylin (8-37), human	Amylin Receptor	Metabolic Disease
Amylin (8-37), human is a fragment of human Amylin. Amylin (8-37), human has direct vasodilator effects in the isolated mesenteric resistance artery of the rat. Human Amylin is a small hormone secreted by pancreatic β-cells that forms aggregates under insulin deficiency metabolic conditions, and it constitutes a pathological hallmark of type II diabetes mellitus .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B1021

Vincamine	Apocynaceae Cardiovascular Disease Alkaloids Structural Classification Classification of Application Fields Source classification Plants Disease Research Fields Indole Alkaloids Catharanthus roseus (L.) G. Don	Free Fatty Acid Receptor
Vincamine is a monoterpenoid indole alkaloid extracted from the Madagascar periwinkle. Vincamine is a peripheral vasodilator and exerts a selective vasoregulator action on the brain microcapilar circulation . Vincamine is a GPR40 agonist and acts as a β-cell protector by ameliorating β-cell dysfunction and promoting glucose-stimulated insulin secretion (GSIS). Vincamine improves glucose homeostasis in vivo, and has the potential for the type 2 diabetes mellitus (T2DM) research .

HY-N10587

Catechin 7-O-β-D-glucopyranoside	Structural Classification other families Classification of Application Fields Phenols Ulmus davidiana var. japonica (Rehd.)Nakai Plants Inflammation/Immunology Disease Research Fields Food Research	Others
Catechin 7-O-beta-D-glucopyranoside is an orally active natural product found in Ulmus davidiana and Paeonia obovata. Catechin 7-O-β-D-glucopyranoside shows antioxidant and anti-inflammatory activities, and attenuates mitochondrial dysfunction. Catechin 7-O-beta-D-glucopyranoside can be used in intestinal inflammatory disease research .

HY-N3419

Kobusone	Structural Classification Natural Products Animals Source classification	Others
Kobusone is a natural compound isolated form Aquilaria sinensis. kobusone can stimulate islet β-cell replication in vivo, and has the potential to be used in diabetic study .

HY-N9363

Corymbiferin	Structural Classification other families Xanthones Classification of Application Fields Source classification Phenols Polyphenols Metabolic Disease Plants Disease Research Fields	Others
Corymbiferin is one of active constituents, responsible for anti-diabetic properties. Corymbiferin improves antioxidant capacity and carbohydrate metabolism in diabetic rats, along with the improvement of histopathology of livers and pancreatic β cells .

HY-N7729

Sekikaic acid	Structural Classification Microorganisms Ketones, Aldehydes, Acids Source classification	Amylases Glucosidase
Sekikaic acid is an α-glucosidase (Glucosidase) and α-amylase (Amylases) inhibitor with hypolipidemic, antioxidant and antidiabetic activities. Sekikaic acid significantly reduces LDL, total cholesterol, and total glyceride levels and causes pancreatic beta cell regeneration .

HY-13753

Streptozotocin 35+ Cited Publications Streptozocin; NSC-85998; U 9889	Structural Classification Microorganisms Classification of Application Fields Antibiotics Source classification Mammalian Cell Culture Disease Research Anticancer Disease Research Fields Other Antibiotics Cancer	DNA/RNA Synthesis DNA Alkylator/Crosslinker Autophagy Bacterial Antibiotic Apoptosis
Streptozotocin (Streptozocin) is an antibiotic widely used in experimental animal models of induced diabetes. Streptozotocin enters B cells via the glucose transporter (GLUT2) and causes the alkylation of DNA ( DNA-methylating ). Streptozotocin can induce the apoptosis of β cells .

HY-129297

CMPF	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
CMPF can be found in trace constituent of urine and blood. CMPF is a biomarker of type 2 diabetes. CMPF can act on the β cell and induces impaired mitochondrial function. CMPF decreases glucose-induced ATP accumulation, and induces oxidative stress. CMPF reverses hepatic lipid accumulation and improves insulin sensitivity in obese mice .

Cat. No.	Product Name	Chemical Structure

HY-B0753S

Gliclazide-d4
Gliclazide-d₄ (S1702 D4) is the deuterium labeled Gliclazide. Gliclazide (S1702) is a whole-cell beta-cell ATP-sensitive potassium currents blocker with an IC50 of 184 nM. Gliclazide is used as an antidiabetic[1].

HY-B0254S

Glipizide-d11
Glipizide-d₁₁ is the deuterium labeled Glipizide. Glipizide (CP 2872; K 4024) a potent, orally active and sulfonylurea class anti-diabetic agent and can be used for type 2 diabetes mellitus research but not type 1. Glipizide acts by partially blocking ATP-sensitive potassium (KATP) channels among β cells of pancreatic islets of Langerhans[1][2].

HY-B0682S2

Mitiglinide-d5 calcium
Mitiglinide-d₅ (calcium) is deuterium labeled Mitiglinide. Mitiglinide (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide can be used for the research of type 2 diabetes[1][2].

HY-B0682S1

(2R)-Mitiglinide-d5 calcium
(2R)-Mitiglinide-d₅ (calcium) is deuterium labeled Mitiglinide. Mitiglinide (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide can be used for the research of type 2 diabetes[1][2].

HY-B0682S

Mitiglinide-d8 calcium hydrate

Mitiglinide-d₈ (calcium hydrate) (KAD-1229-d8) is the deuterium labeled Mitiglinide calcium hydrate. Mitiglinide calcium hydrate (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide calcium hydrate is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide Calcium hydrate can be used for the research of type 2 diabetes[1][2].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks